Yanbin Liang

USPTO Granted Patents = 13 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Irvine, CA (US) (2007 - 2020)
Tustin, CA (US) (2019 - 2021)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11046756 - Heavy chain only antibodies to ANG-2 (2021-06-29),

2. 11028163 - Heavy chain only antibodies to PDGF (2021-06-08),

3. 10752678 - Complement component C5 antibodies (2020-08-25),

4. 10604563 - Nucleic acids encoding anti-complement Factor Bb antibodies (2020-03-31),

5. 10308711 - Heavy chain only antibodies to PDGF (2019-06-04),

6. 10266589 - Heavy chain only antibodies to ANG-2 (2019-04-23),

7. 10093724 - Methods of treating a complement associated eye condition by administering complement factor Bb antibodies (2018-10-09),

8. 9932395 - Nucleic acids encoding complement component C5 antibodies (2018-04-03),

9. 9796776 - Complement factor Bb antibodies (2017-10-24),

10. 9701743 - Complement component C5 antibodies (2017-07-11),

11. 7612082 - [object Object] (2009-11-03),

12. 7320871 - Human prostaglandin FP receptor variants and methods of using same (2008-01-22),

13. 7198928 - Human COX-1 alternatively spliced variants and methods of using same (2007-04-03),

Title: The Innovative Contributions of Yanbin Liang

Introduction

Yanbin Liang is a prominent inventor based in Irvine, California, known for his significant contributions to the field of biotechnology. With a total of 13 patents to his name, Liang has made remarkable advancements in the development of antibodies that target specific proteins involved in various diseases.

Latest Patents

Among his latest patents are the "Heavy chain only antibodies to ANG-2" and "Heavy chain only antibodies to PDGF." The former patent discloses monospecific heavy chain antibodies with antigen-binding specificity to ANG-2, as well as bispecific antibodies that target both ANG-2 and VEGF or PDGF. The latter patent focuses on monospecific heavy chain antibodies with specificity to PDGF, along with bispecific antibodies that can bind to PDGF-2 and VEGF or to PDGF and ANG-2.

Career Highlights

Throughout his career, Yanbin Liang has worked with notable companies such as Allergan, Inc. and Xencor, Inc. His work in these organizations has contributed to the advancement of therapeutic solutions in the biotechnology sector.

Collaborations

Liang has collaborated with esteemed colleagues, including Daniel W. Gil and David Frederick Woodward, further enhancing the impact of his research and innovations.

Conclusion

Yanbin Liang's innovative work in the field of biotechnology, particularly in the development of targeted antibodies, showcases his dedication to advancing medical science. His contributions continue to influence the industry and pave the way for future discoveries.

This text is generated by artificial intelligence and may not be accurate.